Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
McKesson
Cantor Fitzgerald
Mallinckrodt
Deloitte
AstraZeneca
Johnson and Johnson
UBS
Accenture

Generated: June 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,770,295

« Back to Dashboard

Which drugs does patent 6,770,295 protect, and when does it expire?

Patent 6,770,295 protects DETROL LA and is included in one NDA.

Protection for DETROL LA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has one hundred and twenty-eight patent family members in forty-four countries.
Summary for Patent: 6,770,295
Title: Therapeutic formulation for administering tolterodine with controlled release
Abstract:The present invention is drawn to a method of treating an unstable or overactive urinary bladder by treating the patient with tolterodine or a tolterodine-related compound, or pharmaceutically acceptable salt thereof, with a controlled release formulation that maintains a substantially constant serum level of the active moiety or moieties for at least 24 hours. The present invention is further drawn to a formulation for the method.
Inventor(s): Kreilg.ang.rd; Bo (Hillerod, DK), Orup Jacobsen; Lene (Gentofte, DK), Hoeck; Ulla (Hillerod, DK), Kristensen; Helle (Slangerup, DK), Gren; Torkel (Uppsala, SE), Nilvebrant; Lisbeth (Bromma, SE), Ringberg; Anders (Stockholm, SE), Wikberg; Martin (Kullavik, SE), Hallen; Bengt (Sollentuna, SE), Olsson; Birgitta (Stenhamra, SE), Strombom; Jan (Vattholma, SE)
Assignee: Pharmacia AB (Stockholm, SE)
Application Number:09/582,498
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,770,295
Patent Claim Types:
see list of patent claims
Use; Formulation; Dosage form; Delivery; Compound;

Drugs Protected by US Patent 6,770,295

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Pharmacia And Upjohn DETROL LA tolterodine tartrate CAPSULE, EXTENDED RELEASE;ORAL 021228-001 Dec 22, 2000 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Pharmacia And Upjohn DETROL LA tolterodine tartrate CAPSULE, EXTENDED RELEASE;ORAL 021228-002 Dec 22, 2000 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,770,295

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden9802864Aug 27, 1998
Sweden9803871Nov 11, 1998
PCT Information
PCT FiledAugust 26, 1999PCT Application Number:PCT/SE99/01463
PCT Publication Date:March 09, 2000PCT Publication Number: WO00/12069

Non-Orange Book US Patents Family Members for Patent 6,770,295

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,008,637 Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder ➤ Try a Free Trial
6,517,864 Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder ➤ Try a Free Trial
6,911,217 Controlled release bead, a method of producing the same and multiple unit formulation comprising it ➤ Try a Free Trial
6,630,162 Pharmaceutical formulation and its use ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 6,770,295

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 1323 ➤ Try a Free Trial
African Regional IP Organization (ARIPO) 1529 ➤ Try a Free Trial
Argentina 027815 ➤ Try a Free Trial
Argentina 029311 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Colorcon
Cantor Fitzgerald
Julphar
Harvard Business School
AstraZeneca
Federal Trade Commission
Deloitte
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.